GYKI-11679

GYKI-11679 is a new antihypertensive agent.

Signaling Pathways >> Others >> Others

Research Areas >> Cardiovascular Disease

GYKI-11679 is a new antihypertensive agent. Results show a sharp (61%) reduction in the hypothalamic Noradrenaline (NA) level 2 h after the administration of 10 mg/kg of GYKI-11679, and this effect lasts for 4 to 6 h. It is demonstrated that GYKI-11679 exerts a greater NA lowering effect in the hypothalamus than in the periphery. GYKI-11679 does not influence the hypothalamic monoamine oxidase (MAO)-activity following prolonged treatment[1].

Rats are used and treated with GYKI-11679 (0.5 mL of 1% Tween 80 suspension) at various dosages. They are killed at the specified times by decapitation; the heart is immediately removed, cut open, and rinsed in an isotonic saline solution. The brain is placed on ice and the hypothalamus is dissected. The tissues are weighed, homogenized in 5% trichloroacetic acid (TCA) containing 0.2% EDTA and ascorbic acid, and centrifuged for 1 h at 5000×g. The supernatant is processed on alumina and noradrenaline in the eluate is determined spectrofluorimetrically[1].

[1]. Huszti Z, et al. Influence on turnover and level of hypothalamic noradrenaline by a new antihypertensive agent (GYKI 11679). J Neurochem. 1981 Nov;37(5):1272-81.

Captisol | Cyclosporin A | H2DCFDA | 0MPTP hydrochloride | GW4869 | Etomoxir | TD139 | Mitoquinone mesylate | GSK2795039 | JC-1 | BAPTA-AM | AP 20187 | Setanaxib (GKT137831) | D-Luciferin | Crotaline